论文部分内容阅读
目的:探讨新发现的血清标记物B7-H4在乳腺浸润性癌患者血清中的含量变化及其临床诊断价值。方法:通过RT-PCR技术检测确诊为乳腺浸润性癌的58例患者治疗前后及30例健康妇女的血清中B7-H4mRNA含量变化,用ELISA夹心法检测患者血清中的B7-H4分子的水平变化,采用CA125II试剂盒检测所有患者CA125水平的变化,分析比较检测过程中B7-H4分子与CA125分子的特异性与敏感度。结果:RT-PCR检测结果发现大部分乳腺浸润性癌患者血清中B7-H4基因的mRNA含量明显升高(P<0.05);治疗后其水平明显下降但一般仍高于正常水平(P<0.05),Western-blot检测也得到了类似的结果。在乳腺浸润性癌的检测过程中:B7-H4分子的特异度明显低于CA125分子,而其敏感度却明显高于CA125分子;二者联合使用时检测的特异度与敏感度均显著提高(P<0.05)。结论:血清中B7-H4分子的含量升高可以作为一个癌变的高危指标。
Objective: To investigate the serum levels of newly discovered serum marker B7-H4 in patients with invasive breast cancer and its clinical value. Methods: The changes of B7-H4 mRNA in serum of 58 patients diagnosed as breast invasive carcinoma before and after treatment and 30 healthy women were detected by RT-PCR. The level of B7-H4 in sera was detected by ELISA sandwich method , CA125II kit was used to detect the changes of CA125 levels in all patients. The specificity and sensitivity of B7-H4 molecules and CA125 molecules were compared and analyzed. Results: RT-PCR results showed that the mRNA level of B7-H4 in serum of most patients with invasive breast cancer was significantly increased (P <0.05), and the level of B7-H4 mRNA in the patients with invasive breast cancer was significantly lower than the normal level ), Western-blot test also got similar results. In the detection of invasive breast cancer, the specificity of B7-H4 was significantly lower than that of CA125, but its sensitivity was significantly higher than that of CA125. The specificity and sensitivity of B7-H4 were significantly increased P <0.05). Conclusion: The increase of B7-H4 in serum can be used as a high-risk indicator of cancer.